A novel drug class for the effective treatment of Giardia infections

一种有效治疗贾第鞭毛虫感染的新型药物

• 批准号: LP210301109
• 负责人: Prof Adam McCluskey
• 金额: $ 20.36万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2023
• 资助国家: 澳大利亚
• 起止时间: 2023-12-13 至 2026-12-12
• 项目状态: 未结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP210301109
• 关键词: novel; drug; class; effective; treatment

Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent enteric parasite identified globally in dogs. Infection rates can be as high as 75% in puppies. Current treatments are failing due to poor efficacy, resistance and poor adherence to treatment schedules. We have identified a novel, extremely rapid acting series of compounds capable of single shot eradication of Giardia.

伴侣动物在普通澳大利亚家庭的生活方式中起着关键作用。居住在65％的家庭中的900万只猫和狗为业主，尤其是在Covid期间提供了巨大的健康和福祉。确保宠物健康是宠物所有权的主要义务。贾第鞭毛虫感染（Duodenalis，伴有94％的狗的感染为组合A）是全球在狗中鉴定出的最普遍的肠寄生虫。幼犬的感染率可能高达75％。由于疗效，耐药性和对治疗时间表的依从性不佳，目前的治疗方法失败了。我们已经确定了一系列非常快速的表演系列，一系列能够消除贾第鞭毛虫的化合物。